ESTRELLA IMMUNOPHARMA, INC. Current Federal, State and Local, Tax Expense (Benefit)
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Current Federal, State and Local, Tax Expense (Benefit) of $838 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit · last filed 2026-03-18
- ESTRELLA IMMUNOPHARMA, INC. current federal, state and local, tax expense (benefit) for fiscal 2025 was $838.00.
- ESTRELLA IMMUNOPHARMA, INC. current federal, state and local, tax expense (benefit) for fiscal 2024 was $1.63K.
| Period end | Current Federal, State and Local, Tax Expense (Benefit) 6 month | Current Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|---|
| 2025-12-31 | $838.00 10-K · filed 2026-03-18 | |
| 2024-12-31 | $63.00 10-K · filed 2026-03-18 | |
| 2024-06-30 | $1.63K 10-KT · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |